

Chassieu, 24 february 2020

**ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON
13th march 2020
MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE**

The General Meeting of Amoéba shareholders, convened on January 30, 2020 at 10 a.m. at the Company's registered office, did not reach the quorum required to vote on the ordinary and extraordinary resolutions.

Consequently, a new Ordinary and Extraordinary Shareholders' Meeting will be held on second call on:

**Friday 13th march 2020 – 10 am
at the company registered office - 38 Avenue des Frères Montgolfier- 69680 CHASSIEU**

for the purpose of ruling on the same agenda, published in the Bulletin des Annonces Légales Obligatoires (BALO) of 15 January 2020.

The notice of the second convocation including the agenda was published in the Bulletin des Annonces légales Obligatoires (BALO) of February 12, 2020. The terms and conditions of participation and voting at the Meeting are set out in this notice.

The documents stipulated by article R.225-83 of the French commercial code are available to shareholders from the moment that the assembly is convened, in line with the applicable regulatory requirements:

- Any named shareholder can, until the fifth day (inclusive) before the assembly, ask the company to send them these documents. For holders of bearer shares, this right can only be exercised upon presentation of a statement of participation in the accounts of bearer shares held by the authorised intermediary;
- Any shareholder can consult these documents at the company's headquarters during the 15 days preceding the date of the assembly.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn ⁽²⁾ and on the biocontrol market for plant protection estimated



globally at €1.6Bn ⁽⁴⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartement C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE

General Manager

+33 (0)4 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Investors Relations

Grégory BOSSON

Agence Calyptus

+33(0)1 53 65 37 90

gregory.bosson@calyptus.net

Medias relations

Constance LOZET

Agence Ekno

+33(0)7 78 41 19 70

constance.lozet@ekno.fr